↓ Skip to main content

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.

Overview of attention for article published in Clinical Cancer Research, August 2023
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter
3 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
2 Mendeley